Image by squareintheteeth via Flickr

May 4, 2005 

Update

Amylin Pharmaceutical's conference call this afternoon went a long way to clarifying investors' misperceptions surrounding Byetta and the FDA's labeling of the drug. The company also reinforced the market potential of the drug. And the market potential for Byetta is big.Read more...